Zydus Lifesciences shares touched a two-year peak, bolstered by strong demand for chronic therapies and a growing pipeline of complex products. While revenue grew 22% in the recent quarter, investors are weighing this against a 36% decline in net profit and a premium valuation of 25 times FY28 earnings.
Zydus Lifesciences has reached a two-year high in its share price, marking a 33% gain over the past six months. This move comes as the company continues to focus on its domestic chronic therapy portfolio, which now contributes 54% of its trailing 12-month revenue. The strategy involves a shift toward high-value, innovation-led products rather than relying solely on generic medicines.
While the market has responded positively to this operational shift, the company’s recent financial results present a more nuanced picture. In the first quarter of FY27, Zydus Lifesciences reported a 22% increase in revenue, reaching ₹8,017 crore. However, its net profit dropped by 36% compared to the previous year. This discrepancy suggests that while sales are growing, the company is dealing with significant pressure on profit margins. This pressure is largely driven by increased spending on research, development, and the launch of specialty and complex products aimed at long-term growth.
Investors are now assessing whether this trade-off between current profitability and future growth is sustainable. The stock currently trades at roughly 25 times its FY28 earnings estimates, which is higher than its five-year historical average. Because of this valuation premium, some analysts are maintaining a cautious view, waiting to see if the company can improve its margins while scaling its complex product pipeline, which includes biosimilars and transdermal medications.
On the operational front, the company has seen success with USFDA inspections, which recently resulted in nil observations at its key facilities. This regulatory clarity is important for the company as it seeks to stabilize its supply chain and launch new products in the US market. Additionally, Zydus has extended its investment deadline for a joint venture with Sunshine Healthcare Lanka to December 2026, signaling a continued focus on its international partnerships.
The next steps for investors will be to track whether the company can translate its revenue growth into better bottom-line performance. The key monitorable remains the successful execution of its complex product launches and whether these high-value segments can eventually lead to margin expansion, justifying the current valuation levels.